This shift in the frontline, intensive treatment of AML patients has resulted in a requirement for a more rapid turn-around of cytogenetic and FLT3 testing (e.g., ~<1 week) to facilitate appropriate therapy selection. The gene discussed is FLT3; the disease is acute myeloid leukemia.